Seeking Formulation of New Drug, Biopharma Co. Signs LOI
Research Report

1. Rakovina Therapeutics has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rakovina Therapeutics.
3. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 

For additional disclosures, please click here.

Disclosures for Leede Financial Inc., Rakovina Therapeutics, August 22, 2025

Leede Financial Inc. (Leede) is a member of the Canadian Investment Regulatory Organization (CIRO) and a member of the Canadian Investor Protection Fund (CIPF). This document is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular investing strategy. Data from various sources were used in the preparation of these documents; the information is believed but in no way warranted to be reliable, accurate and appropriate. All information is as of the date of publication and is subject to change without notice. Any opinions or recommendations expressed herein do not necessarily reflect those of Leede. Leede cannot accept any trading instructions via e-mail as the timely receipt of e-mail messages, or their integrity over the Internet, cannot be guaranteed. Dividend yields change as stock prices change, and companies may change or cancel dividend payments in the future. All securities involve varying amounts of risk, and their values will fluctuate, and the fluctuation of foreign currency exchange rates will also impact your investment returns if measured in Canadian Dollars. Past performance does not guarantee future returns, investments may increase or decrease in value, and you may lose money. Leede employees may buy and sell shares of the companies that are recommended for their own accounts and for the accounts of other clients. Disclosure codes are used in accordance with Policy 3600 of CIRO. Description of Disclosure Codes 1. Leede and its affiliates collectively beneficially own 1% or more of any class of equity securities of the company as of the end of the preceding month or the month prior to the preceding month if the report was issued prior to the 10th. 2. The analyst or any associate of the analyst responsible for the report or public comment hold shares or is short any of the company's securities directly or through derivatives. 3. Leede or a director or officer of Leede or any analyst provided services to the company for remuneration other than normal investment advisory or trade execution services within the preceding 12 months. 4. Leede provided investment banking services for the company during the 12 months preceding the publication of the research report. 5. Leede expects to receive or intends to seek compensation for investment banking services in the next three months. 6. The analyst preparing the report received compensation based upon Leede investment banking revenues for this issuer within the preceding 12 months. 7. The director, officer, employee, or research analyst is an officer, director or employee of the company, or serves in an advisory capacity to the company. 8. Leede acts as a market maker of the company. 9. The analyst has conducted a site visit and has viewed a major facility or operation of the issuer. 10. The company has paid for all, or a material portion, of the travel costs associated with the site visit by the analyst. Dissemination All final research reports are disseminated to existing and potential institutional clients of Leede Financial Inc. (Leede) in electronic form to intended recipients thorough e-mail and third-party aggregators. Research reports are posted to the Leede website and are accessible to customers who are entitled to the firm’s research. Reproduction of this report in whole or in part without permission is prohibited. Research Analyst Certification The Research Analyst(s) who prepare this report certify that their respective report accurately reflects his/her personal opinion and that no part of his/her compensation was, is, or will be directly or indirectly related to the specific recommendations or views as to the securities or companies. Leede Financial Inc. (Leede) compensates its research analysts from a variety of sources and research analysts may or may not receive compensation based upon Leede investment banking revenue. Canadian Disclosures This research has been approved by Leede Financial Inc. (Leede), which accepts sole responsibility for this research and its dissemination in Canada. Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). Canadian clients wishing to effect transactions in any designated investment discussed should do so through a Leede Registered Representative. U.S. Disclosures This research report was prepared by Leede Financial Inc. (Leede). Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). This report does not constitute an offer to sell or the solicitation of an offer to buy any of the securities discussed herein. Leede is not registered as a broker-dealer in the United States and is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. Any resulting transactions should be affected through a U.S. broker-dealer.

Rakovina Therapeutics Inc. (RKV:TSX.V), a British Columbia-based artificial intelligence (AI)-powered cancer therapy developer, signed a letter of intent earlier this month with NanoPalm, a lipid nanoparticle innovator in Saudi Arabia, in regards to formulation of Rakovina's anticancer drug kt3283, reported Dr. Douglas Loe, managing director and analyst at Leede Financial Inc., in an August 22 Week in Review note.

"It is no surprise that the firm consummated a letter of intent with one lipid nanoparticle innovator that has documented expertise in cancer drug delivery," Loe wrote.

This is because Rakovina has been looking for a novel formulation or drug delivery modalities that could modify kt3283's pharmacokinetics to be more tumor-targeted. The prospects are nanoparticle technologies and cancer antigen-targeted monoclonal antibodies to which kt3283 could be covalently bound.

Tumor Targeting is Goal

Loe explained that Rakovina's kt3283 is a first-generation drug that inhibits both PARP and HDAC enzymes, well validated as being relevant to cancer cell growth and division. PARP, or poly-ADP ribose polymerase, is involved in DNA replication. HDAC, or histone deacetylase, removes acetyl groups from DNA-wrapped histones. Rakovina seeks to identify small molecules that inhibit these two targets at the same time. The inhibition of each enzyme is involved in several U.S. Food and Drug Administration (FDA)-approved therapies.

The pharmacokinetics of kt3283 were published in Clinical Cancer Research in 2023. The paper noted the drug showed "enhanced" cytotoxicity in at least one cancer model, a mouse model for an aggressive bone cancer affecting children and young adults called Ewing's sarcoma. This means kt3283 exhibited greater anti-tumor activity than representative PARP inhibitors like AstraZeneca's Lynparza (olaparib) and HDAC inhibitors such as Merck's Zolinza (vorinostat) did individually. Further, kt3283 did so at a lower concentration than Lynparza and Zolinza would require to show their clinical anticancer activity.

What NanoPalm Does

Since its founding in 2022, NanoPalm's researcher Dr. A.H. Alhasan has been using AI tools to develop lipid nanoparticles as vehicles for delivering gene therapies and small molecules in a disease-targeted, organ-specific way, reported Loe. For many years, Alhasan has researched various drug formulation and drug delivery modalities, not just lipid-based technologies. Reportedly, NanoPalm's AI engine EnsaliX can develop stable lipid nanoparticles target specific organs and cells, something current lipid nanoparticle-based therapies cannot do.  

Little to no published information exists on this technology of NanoPalm or on the AI engine behind it. However, one study published in iScience in 2022 explains that the company's methodologies create nanopalms. These are supramolecular lipid particles, or lipid micelle precursors formed into various secondary structures (sheets, discs, tubes, ribbons, cochleates/shell shapes). To guide lipid assembly into a shape, whichever one a particular application requires, NanoPalm uses "patterning-mediated self-assembly and polymer pen lithography." In past work, the shapes remained stable for at least four months after they were formed.

"It is far too early to predict if NanoPalm-derived lipid structures could be useful in facilitating kt3283's tumor-targeted delivery," Loe wrote. That said, "the concept of formulating kt3283 in a lipid nanoparticle is certainly a plausible path forward."

Secondary Structure is Key

Loe noted that a number of FDA-approved lipid nanoparticle-based anti-cancer drugs exist already. Ones mentioned in a 2023 article in the International Journal of Molecular Sciences, for example, include Marqibo (discontinued in 2020), Doxil, Onivyde and Vyxeos. The lipid composition in them varies from drug to drug, but little to no mention is made of the secondary structure of the lipid formulations themselves.

"We will be interested to see if NanoPalm's focus on lipid nanoparticle secondary structure does indeed facilitate tissue targeting of kt3283 in ways not currently achievable with conventional liposome formulations," wrote Loe.